BIIB

Q: What is the price of Biogen (BIIB) today?

The price of Biogen (BIIB) today is $ 195.13, with return of 38.13% compared to the last year. The price of Biogen (BIIB) started the year trading around $ 175.99 and today it is at $ 195.13. Follow the real-time price chart, the historical price of Biogen (BIIB) and international markets.

Q: When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not distribute dividends in the last year.

Q: Is Biogen (BIIB) worth it?

Currently, Biogen (BIIB) is priced at $ 195.13, with a P/E of 21.83%, representing a deviation of 1,633% from its historical average P/E. In the last year, the stock showed a variation of 38.13 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 38.13%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Biogen (BIIB) stock?

Investing in stocks of Biogen (BIIB) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Biogen (BIIB) yield today?

The yield of Biogen (BIIB) was 13.72% in the last month, 38.13% in the last year and -28.49% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Biogen (BIIB) today, the total investment would be $ 19,513.00, based on the current price of $ 195.13.If past performance were to repeat, the return on your investment would be:In 1 year: $ 26,953.31In 5 years: $ 13,953.75In 10 years: $ 14,677.68It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Biogen Inc.

Price

$ 195.13

return (12m)

38.13%

p/e

21.83

p/b

1.55

DIVIDEND YIELD

0.00%

price BIIB

BIIB

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of BIIB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

13.72%

3 months

7.25%

1 year

38.13%

2 years

-12.62%

5 years

-28.49%

10 years

-24.78%

Fundamentals BIIB

review the fundamentals of Biogen shares

P/E

21.83

Sector: -3.67 Industry: -3.67

P/S (Price-to-Sales)

2.85

Sector: -3.88 Industry: -3.88

P/B

1.55

Sector: 1.96 Industry: 1.96

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

4.39%

Sector: -64.91% Industry: -64.91%

ROE

7.08%

Sector: -66.87% Industry: -66.87%

ROIC

5.98%

Sector: -1,295.86% Industry: -1,295.86%

NET MARGIN

13.07%

Sector: -41.02% Industry: -41.02%

GROSS MARGIN

75.69%

Sector: 38.71% Industry: 38.71%

OPERATING MARGIN

24.96%

Sector: -40.91% Industry: -40.91%

EV/EBITDA

10.84

Sector: -3.69 Industry: -3.69

EV/EBIT

15.48

Sector: -3.83 Industry: -3.83

PRICE-TO-ASSETS

0.96

Sector: 1.43 Industry: 1.43

BVPS

124.20

Sector: 1.76 Industry: 1.76

EPS

8.80

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.62

Sector: 0.40 Industry: 0.40

LIABILITIES / ASSETS

0.38

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

-2.07%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-3.64%

Sector: - Industry: -

FAIR VALUE OF Biogen ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 195.13

Fair Value

$ 0.00

Upside Return potential.

-19.63%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BIIB

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/b	ROE	dy	market cap	net margin
JNJ	21.68	7.33	33.81%	2.13%	$ 581.04 B	28.46%
PFE	19.50	1.63	8.35%	6.45%	$ 151.53 B	12.42%
ABBV	94.00	0.00	0.00%	2.96%	$ 397.24 B	6.91%
NVO	13.44	6.92	51.50%	3.56%	$ 210.59 B	33.05%
MRK	16.62	0.00	0.00%	2.68%	$ 303.45 B	28.08%
AZN	30.72	6.45	20.99%	0.77%	$ 314.12 B	17.41%
GILD	22.10	8.31	37.62%	2.09%	$ 188.04 B	28.90%
BMY	17.51	-3.63	-20.72%	4.10%	$ 123.50 B	14.64%
ZTS	21.10	16.93	80.25%	1.55%	$ 56.41 B	28.23%
REGN	17.83	2.57	14.41%	0.45%	$ 80.31 B	31.41%
HALO	13.95	16.48	118.17%	0.00%	$ 8.30 B	47.91%
AMGN	26.20	23.33	89.06%	2.54%	$ 201.99 B	20.98%
MCK	26.85	-1,177.17	-4,383.84%	0.32%	$ 116.54 B	1.09%
VRTX	30.64	6.49	21.18%	0.00%	$ 121.13 B	32.94%
CAH	31.87	-19.62	-61.56%	0.91%	$ 52.97 B	0.68%
ADMA	18.37	8.92	48.57%	0.00%	$ 3.85 B	42.87%
HRMY	9.11	2.03	22.24%	0.00%	$ 1.69 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

BIIB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT THE COMPANY Biogen

Biogen Inc.

Average user rating I10

4.0 (15 people)

United States

48 years

Founded: 1978

1991

Time since IPO - 35 years

9.100

Employees

The Company Biogen Inc. (United States), is listed on Nasdaq with a market value of $ 28.23 Billions, having an equity of $ 18.26 Billions.

With a total of 9.100 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 9.89 Billions, which generated a loss in the amount of $ 1.29 Billion.

As for its main indicators, the Company has a P/E ratio of 21.83, a P/BV ratio of 1.55 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker BIIB.

Market cap

$ 28.23 Billions

Net worth

$ 18.26 Billions

US$ 18,256,800,000.00

Assets

$ 29.44 Billions

US$ 29,439,500,000.00

Total Shares Outstanding

147.00 Millions

147,000,000

Average Daily Trading Volume

$ 1.88 Million

US$ 1,881,018.00

Sector

Health Care

Industry

Biotechnology

BIIB

BIIB revenue and profits

Financial Results BIIB

DRAG THE FRAME TO SEE MORE DATA

BIIB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/B

0.00

MCK - McKesson

$ 957.36 53,45% (12M)

P/E

26.85

0.32%

ROE

-4,383.84%

P/B

-1,177.17

CAH - Cardinal Health

$ 225.97 79,43% (12M)

P/E

31.87

0.91%

ROE

-61.56%

P/B

-19.62

JNJ - Johnson & Johnson

$ 246.28 53,64% (12M)

P/E

21.68

2.13%

ROE

33.81%

P/B

7.33

PFE - Pfizer

$ 27.14 10,66% (12M)

P/E

19.50

6.45%

ROE

8.35%

P/B

1.63

ABBV - AbbVie

$ 228.44 15,61% (12M)

P/E

94.00

2.96%

ROE

0.00%

P/B

0.00

MRK - Merck & Co.

$ 123.93 41,63% (12M)

P/E

16.62

2.68%

ROE

0.00%

P/B

0.00

AZN - AstraZeneca

$ 206.61 182,81% (12M)

P/E

30.72

0.77%

ROE

20.99%

P/B

6.45

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 957.36 53,45% (12 M)

P/L

26.85

0.32%

ROE

-4,383.84%

P/VP

-1,177.17

CAH - Cardinal Health

$ 225.97 79,43% (12 M)

P/L

31.87

0.91%

ROE

-61.56%

P/VP

-19.62

JNJ - Johnson & Johnson

$ 246.28 53,64% (12 M)

P/L

21.68

2.13%

ROE

33.81%

P/VP

7.33

PFE - Pfizer

$ 27.14 10,66% (12 M)

P/L

19.50

6.45%

ROE

8.35%

P/VP

1.63

ABBV - AbbVie

$ 228.44 15,61% (12 M)

P/L

94.00

2.96%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 123.93 41,63% (12 M)

P/L

16.62

2.68%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 206.61 182,81% (12 M)

P/L

30.72

0.77%

ROE

20.99%

P/VP

6.45

Frequently Asked Questions

What is the price of Biogen (BIIB) today?

The price of Biogen (BIIB) today is $ 195.13, with return of 38.13% compared to the last year. The price of Biogen (BIIB) started the year trading around $ 175.99 and today it is at $ 195.13. Follow the real-time price chart, the historical price of Biogen (BIIB) and international markets.

When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not distribute dividends in the last year.

Is Biogen (BIIB) worth it?

Currently, Biogen (BIIB) is priced at $ 195.13, with a P/E of 21.83%, representing a deviation of 1,633% from its historical average P/E. In the last year, the stock showed a variation of 38.13 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 38.13%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Biogen (BIIB) stock?

Investing in stocks of Biogen (BIIB) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Biogen (BIIB) yield today?

The yield of Biogen (BIIB) was 13.72% in the last month, 38.13% in the last year and -28.49% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Biogen (BIIB) today, the total investment would be $ 19,513.00, based on the current price of $ 195.13.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 26,953.31
In 5 years: $ 13,953.75
In 10 years: $ 14,677.68

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

BIIB

Biogen Inc.

Price

return (12m)

p/e

p/b

DIVIDEND YIELD

Return of BIIB

review the fundamentals of Biogen shares

P/E

P/S (Price-to-Sales)

P/B

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT THE COMPANY Biogen

Biogen Inc.

United States

48 years

1991

9.100

PROFIT X PRICE BIIB

Financial Results BIIB

BIIB cash flow

asset growth - BIIB

BIIB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions